SCHEMBL25302014

SCHEMBL25302014

CCOC(=O)c1ncc(C)nc1N1CCC(C)(CNC(=O)OC(C)(C)C)CC1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 1/20 0.36
SKP1 P63208 1/20 0.36
SKP2 Q13309 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
PKM P14618 1/20 0.35
MTOR P42345 5/20 0.35
ADORA3 P0DMS8 1/20 0.34
ADORA2A P29274 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TSHR P16473 1/20 0.34
HTR2C P28335 1/20 0.34
MAPKAPK2 P49137 1/20 0.34
OPRK1 P41145 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31013067 1.00 CKS1B (0.36) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL30511919 0.87 RET (0.43) MEN1KMT2AL3MBTL1PKMMTOR
SCHEMBL19785534 0.87 RET (0.43) MEN1KMT2AL3MBTL1PKMMTOR
SCHEMBL31000346 0.84 MAPKAPK2 (0.37) CKS1BSKP1SKP2MAPKAPK2
SCHEMBL30484961 0.83 MEN1 (0.34) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL25302989 0.83 MEN1 (0.34) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL19785573 0.80 OPRK1 (0.36) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL30511956 0.80 OPRK1 (0.36) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL30511930 0.80 OPRK1 (0.36) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL30296108 0.80 OPRK1 (0.36) CKS1BSKP1SKP2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250109118-A1 HETEROCYCLIC COMPOUNDS AS SHP2 INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF JS INNOMED HOLDINGS LTD. (KY) 2025-04-03 US disclosed
WO-2023122938-A1 HETEROCYCLIC COMPOUNDS AS SHP2 INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF JS INNOMED HOLDINGS LTD. (KY) 2023-07-06 WO disclosed
WO-2023122938-A1 HETEROCYCLIC COMPOUNDS AS SHP2 INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF JS INNOMED HOLDINGS LTD. (KY) 2023-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250109118-A1 HETEROCYCLIC COMPOUNDS AS SHP2 INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF PTPN1, PTPN5, PTPN13 CKS1B 1032/4885SKP1 499/4885SKP2 542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.